Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

BIIB is a target "takeover".

|Includes: AZN, Biogen Inc. (BIIB), BMY

large-cap pharmaceutical co... AZN, BMY, and SNY would be possible buyers.  This especially makes sense if the buyer is looking for a great Phase III drug pipeline.  &... at the current price, trades at 12 times  2009 earnings estimate of $4.08 a share. The stock's price-earnings ratio is below that of the biotech's peer group, which includes Genzyme, Gilead and Celgene